It seems to be in our nature to think of things as binary: you prefer the beach over the mountains; you like sweet treats rather than salty; this is correct and that is wrong.
Following DTx West 2023 in San Mateo, California, back in February, Woebot Health’s chief clinical officer Athena Robinson spoke with pharmaphorum about the conversations had at the event,
Roche has broken new ground with its ALK inhibitor Alecenesa, becoming the first drug in the class to be approved by the FDA for adjuvant use after surgery in early-stage,
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.